What we hope to achieve

AMYPAD aims to determine the value of ß-amyloid imaging as a diagnostic and therapeutic marker for Alzheimer’s disease.

3 main project objectives

Click on each section below to find out more about the main AMYPAD project objectives.

Diagnostic value: Usefulness of ß-amyloid imaging in patient management Diagnostic study #1590AF First, the project aims at better understanding the impact of the utilization of amyloid PET imaging on diagnostic thinking and patient management.
AMYPAD will scan a large population cohort (n=900) suspected of possible Alzheimer’s disease, focusing on those with subjective cognitive decline (SCD), mild cognitive impairment (MCI) and atypical/unexplained dementia, to determine the usefulness of ß-amyloid imaging regarding diagnostic confidence, decision trees, change in diagnosis, and patient management plans. The primary objective is to measure the impact on patient management of early versus late utilization of amyloid PET imaging
Risk stratification: Natural history of disease and methods to enrich secondary prevention studies Prognostic study #2B599B Second, the project wants to follow up and understand the natural history of Alzheimer’s disease ranging from cognitively normal, through subjective cognitive decline towards mild cognitive impairment in order to define the optimal window of opportunity for secondary prevention of Alzheimer’s disease through ß-amyloid PET imaging.
To better understand the natural history of ß-amyloid pathophysiology, AMYPAD will leverage a Europe-wide network in close collaboration with EPAD to study the earliest stages of Alzheimer’s disease in a longitudinal fashion.
Monitoring treatment: Quantifying patient-specific efficacy Proof of concept studies #514A89 Finally, AMYPAD will select people for treatment trials aiming at preventing Alzheimer’s disease by ensuring more homogeneous and appropriate enrolment.
The combined populations will be followed clinically and in up to 50% with longitudinal ß-amyloid imaging (focusing on those with borderline positive scans) to improve understanding of disease pathophysiology and establish relevant pre-trial information that will facilitate clinical trial inclusion, reduce required sample size and improve statistical power of the (imaging-related) outcomes. The ultimate goal is to establish predictors of decline to help in the planning and monitoring of treatment.
Diagnostic study First, the project aims at better understanding the impact of the utilization of amyloid PET imaging on diagnostic thinking and patient management.
AMYPAD will scan a large population cohort (n=900) suspected of possible Alzheimer’s disease, focusing on those with subjective cognitive decline (SCD), mild cognitive impairment (MCI) and atypical/unexplained dementia, to determine the usefulness of ß-amyloid imaging regarding diagnostic confidence, decision trees, change in diagnosis, and patient management plans. The primary objective is to measure the impact on patient management of early versus late utilization of amyloid PET imaging
About the AMYPAD study
 

AMYPAD officially started on 1 October 2016 and has a duration of five years. The project involves 15 academic and private research partners.

Led by VU University Medical Center Amsterdam , the AMYPAD consortium brings together a word-class team of highly synergistic partners from across Europe to form a pan- European network including the most active PET sites. This will ensure effective access to patients and also maximise exposure to technical knowledge and disease modelling.

In addition, AMYPAD will address the above goals in close collaboration with IMI project EPAD (the European Prevention of Alzheimer’s Disease project) in a public-private initiative. Together with IMI’s EMIF-AD, AETIONOMY and EPAD projects, AMYPAD forms the IMI Alzheimer’s disease platform.

To keep the project aligned with the current state-of-the-art of the field, regular interactions with external experts and complementary initiatives are envisioned, allowing maximal leverage
of novel knowledge into the AMYPAD Project. In this context, a scientific advisory board was
set up to provide additional independent expertise and knowledge on scientific, technical, communications, ethical and political matters.